Hypercapnic burden in adults with obesity undergoing diagnostic polysomnography for suspected obstructive sleep apnea: a prospective observational cohort study
NCT ID NCT07809061
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
Obesity-related sleep hypoventilation represents a continuum ranging from isolated nocturnal hypoventilation to obesity hypoventilation syndrome. Current diagnostic criteria rely mainly on dichotomous thresholds and may not adequately reflect cumulative nocturnal carbon dioxide exposure. Hypercapnic burden, defined as the cumulative area under the transcutaneous carbon dioxide (PtcCO₂) curve above a predefined threshold, has recently emerged as a novel physiological marker integrating both the intensity and duration of nocturnal hypercapnia. This prospective observational cohort study aims to evaluate the association between nocturnal hypercapnic burden and obstructive sleep apnea severity, assessed by the apnea-hypopnea index (AHI), in adults with obesity referred for diagnostic polysomnography. Secondary objectives include evaluating associations between hypercapnic burden and sleep architecture, respiratory events, oxygenation parameters, daytime symptoms, and patient-reported outcomes. In addition, the study will investigate the relationship between nocturnal hypercapnic burden and sleep inertia, assessed using the Sleep Inertia Questionnaire (SIQ), based on the hypothesis that greater nocturnal carbon dioxide exposure immediately before awakening may contribute to impaired alertness upon awakening. Hypothesis: Increased nocturnal hypercapnic burden is associated with greater obstructive sleep apnea severity and reflects an additional physiological dimension of obesity-related sleep hypoventilation beyond conventional polysomnographic indices. Furthermore, higher nocturnal hypercapnic burden is hypothesized to be associated with greater sleep inertia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * Body mass index (BMI) ≥30 kg/m². * Referred to the Sleep Medicine Center for routine diagnostic polysomnography because of suspected obstructive sleep apnea. * Affiliated with a French health insurance scheme. * Received information about the study and did not object to the use of their data. * Able to understand the study information and complete study questionnaires. Exclusion Criteria: * Legal incapacity or inability to provide non-opposition to participation. * Previous treatment with continuous positive airway pressure (CPAP) or non-invasive ventilation. * Participation in another interventional clinical study that could interfere with the present study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity (bmi>30) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Croix-Rousse Hospital, Hospices Civils de Lyon
Lyon, 69004, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-world evaluation of the clinical performance and safety of apneal dx for the screening and aid in the diagnosis of obstructive sleep apnea-hypopnea syndrome in adults: a post-market clinical follow-up study
- Can a small breathing hurdle ease sleep apnea?
- Can a weekly shot ease sleep apnea in obesity?
- Can a Mini-Dose drug combo rescue Post-Surgery sleep for sleep apnea patients?
- Could a treadmill tame sleep apnea and calm brain inflammation?
- Stomach suturing may lighten the load on failing hearts